{"protocolSection":{"identificationModule":{"nctId":"NCT04427241","orgStudyIdInfo":{"id":"kuhrm2020no1"},"organization":{"fullName":"Konkuk University Medical Center","class":"OTHER"},"briefTitle":"Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness","officialTitle":"Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness in Patients With Hemorrhagic Stroke: A Pilot Study"},"statusModule":{"statusVerifiedDate":"2023-05","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-06-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-07-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-06-03","studyFirstSubmitQcDate":"2020-06-08","studyFirstPostDateStruct":{"date":"2020-06-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-05-25","lastUpdatePostDateStruct":{"date":"2023-05-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Jongmin Lee, MD, PhD","investigatorTitle":"Professor","investigatorAffiliation":"Konkuk University Medical Center"},"leadSponsor":{"name":"Konkuk University Medical Center","class":"OTHER"},"collaborators":[{"name":"Ever Neuro Pharma GmbH","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Object: To determine the effect of cerebrolysin on prolonged disorders of consciousness caused by hemorrhagic stroke.\n\nParticipants: patients with prolonged disorders of consciousness due to severe traumatic brain injury\n\nIntervention: 30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously or 100 ml normal saline, days 4-17, once/day, IV\n\nComparison: cerebrolysin group versus control group\n\nOutcome: Coma Recovery Scale-revised, FDG-PET signal"},"conditionsModule":{"conditions":["Disorder of Consciousness","Hemorrhagic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":12,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cerebrolysin","type":"EXPERIMENTAL","description":"30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously","interventionNames":["Drug: Cerebrolysin"]},{"label":"Control","type":"PLACEBO_COMPARATOR","description":"100 ml normal saline, days 4-17, once/day, IV","interventionNames":["Drug: Control"]}],"interventions":[{"type":"DRUG","name":"Cerebrolysin","description":"30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously","armGroupLabels":["Cerebrolysin"]},{"type":"DRUG","name":"Control","description":"100 ml normal saline, days 4-17, once/day, IV","armGroupLabels":["Control"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Coma Recovery Scale - revised","description":"Assessing the degree of disorders of consciousness","timeFrame":"2 days after randomization"},{"measure":"Coma Recovery Scale - revised","description":"Assessing the degree of disorders of consciousness","timeFrame":"17 days after randomization"},{"measure":"Positron Emitting Tomography","description":"Assessing the degree of brain neural network activity","timeFrame":"2 days after randomization"},{"measure":"Positron Emitting Tomography","description":"Assessing the degree of brain neural network activity","timeFrame":"17 days after randomization"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n1. Patients with hemorrhagic stroke confirmed by CT or MRI\n2. Patients who have been in disorders of consciousness for more than 4 weeks after the onset of hemorrhagic stroke\n3. Patients in a vegetative state or minimally conscious state (Coma Recovery Scale -revised: CRS-R assessment)\n4. Age: 19 to 80 years of age\n5. Patients who have voluntarily given written informed consent to participate in the study by themselves or their legal representative.\n\nExclusion Criteria\n\n1. Patients with confirmed epileptiform discharges on EEG\n2. Patients with brain parenchymal defects\n3. Patients with advanced liver, kidney, cardiac, or pulmonary disease.\n4. Chronic treatment with medications that may affect consciousness, such as antidepressants, antipsychotic drugs, nootropic drugs, and vasodilators.\n5. History of serious illness within the last two years (cancer, hematologic, renal, hepatic, or coronary artery disease, psychiatric illness, diabetes, myocardial infarction, epilepsy), no evidence of secondary damage to major organs, and well-controlled diabetes or hypertension.\n6. Alcohol or drug abuse or dependence within the last 2 years (DSM-V criteria).\n7. Significant systemic disease or unstable medical condition that may compromise compliance with the study protocol.\n8. Administration of a contraindicated drug is essential for medical purposes.\n9. Contraindications to the study drug (cerebrolysin).\n10. Participation in another therapeutic study","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Konkuk University Medical Center Research Coordinating Center","city":"Seoul","country":"Korea, Republic of","contacts":[{"name":"Mi Soo Jang, Ph.D.","role":"CONTACT","phone":"20305474","phoneExt":"+822","email":"rcc@kuh.ac.kr"}],"geoPoint":{"lat":37.566,"lon":126.9784}}]},"referencesModule":{"references":[{"pmid":"32057086","type":"BACKGROUND","citation":"Lee S, Lee HH, Lee Y, Lee J. Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study. J Rehabil Med. 2020 Feb 27;52(2):jrm00025. doi: 10.2340/16501977-2654."},{"pmid":"22375973","type":"BACKGROUND","citation":"Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, Yablon SA, Luther M, Hammond FM, Nordenbo A, Novak P, Mercer W, Maurer-Karattup P, Sherer M. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012 Mar 1;366(9):819-26. doi: 10.1056/NEJMoa1102609."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000003244","term":"Consciousness Disorders"},{"id":"D000083302","term":"Hemorrhagic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000019954","term":"Neurobehavioral Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000019965","term":"Neurocognitive Disorders"},{"id":"D000001523","term":"Mental Disorders"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M2405","name":"Hemorrhagic Stroke","asFound":"Hemorrhagic Stroke","relevance":"HIGH"},{"id":"M6158","name":"Consciousness Disorders","asFound":"Disorders of Consciousness","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21516","name":"Neurobehavioral Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"},{"id":"M21526","name":"Neurocognitive Disorders","relevance":"LOW"},{"id":"M4505","name":"Mental Disorders","relevance":"LOW"},{"id":"M14163","name":"Psychotic Disorders","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"C000006952","term":"Cerebrolysin"}],"ancestors":[{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018697","term":"Nootropic Agents"}],"browseLeaves":[{"id":"M351658","name":"Cerebrolysin","asFound":"VII","relevance":"HIGH"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}